


ARREST

#AHA20



Trial Description: Phase II, single center, partially blinded, prospective, intention to treat, safety and efficacy clinical trial comparing survival to hospital discharge in patients with refractory VT/VF and OHCA treated with early ECMO-facilitated resuscitation (n = 15) versus standard ACLS resuscitation (n = 15).



RESULTS

- Primary outcome, survival to hospital discharge: ECMO vs. standard ACLS: 43.0% vs. 7.0%; posterior probability = 0.99
- Secondary outcome, survival to 3 and 6 months: ECMO vs. standard ACLS: 43.0% vs. 0.0%; p = 0.0063 in both cases

CONCLUSIONS

- Among patients with OHCA and refractory VF, early ECMO-facilitated resuscitation significantly improved survival to hospital discharge in 3 and 6 months compared to standard ACLS treatment.

Yannopoulos D, et al. Lancet 2020;Nov 13:[Epub].